JPM Final PSS 1 13 2020 for PDF - NantKwest...ImmunityBio, Inc. & NantKwest Inc. –JP Morgan...

!"#$%&'()#*+(,-./(&+#0%)1+&+)/+!()2(&3#456#7878

9.+#:+(;<)'#:(-+#=-('+#>??2)%-.+&(@3#0%?@()<+A*(&)+AA<)'#>??2)%'+)</#0+,,#B+(-.

4

!""#$%&#'%&(")*+),&((

*-$./-()+0((&/1*+2),&((

*+),&(()# 34/5)$4)+0((6!"#$%&'()*+,,&%)-&,,

.//"#&).00$/&)12(#&0

!*345

!"#$%&'&(&)$*)&+,-./01!"#$%&'&(&)$*)&+,-./01

%&+)/.(.2$3&''

%&+)/.(.2$3&''$4 56&$5/7.+&/8!"#$%&'()*%"+,&%)-&..

*/&)-%0(()*".1)2&#3&&,)4,,"#&)5)67"8#+9&)4::$,&);<(#&:

!"#$%&'()*+,&-.+/0*,

102+.3&4*550.6&7055

6&7055&# 6.8*,09&/+&4*55:!"#$%&'()*"%+&#&,)-.//&%0,"1#.2&)344$5&)67(#&4

*89

ImmunityBio, Inc. & NantKwest Inc. – JP Morgan Healthcare Conference 2020

GENERAL DISCLAIMERNot all product candidates and/or services referenced in these slides are proprietary to NantKwest or ImmunityBio and may be owned or controlled by third parties, including their affiliates.

FORWARD-LOOKING STATEMENTSThese slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that are based on

management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to:

• our ability to pioneer immunotherapy, harness the power of the innate immune system, implement precision cancer medicine and change the current paradigm of cancer care;

• our expectations regarding the potential benefits of our strategy and technology;

• our ability to utilize multiple modes to induce cell death;

• our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry;

• our beliefs regarding the success, cost and timing of our product candidate development activities and clinical trials;

• the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug (IND) filings or pursuit of accelerated regulatory approval pathways or

orphan drug status and breakthrough therapy designations;

• our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem;

• our expectations regarding our ability to utilize the Phase I aNK clinical trial data to support the development our other product candidates;

• our ability to produce an “off-the-shelf” therapy;

• our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates;

• our ability to obtain and maintain intellectual property protection for our product candidate and not infringe upon the intellectual property of others;

• the ability and willingness of strategic collaborators, including certain of our affiliates, to share our vision and effectively work with us to achieve our goals;

• the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities; and

• regulatory developments in the United States and foreign countries.

Factors that could cause our results to differ materially from those expressed in forward-looking statements include, without limitation: • the fact that our business is based upon the success of aNK cells as a technology platform and the success of N-803 and the other product candidates;

• our aNK platform and other product candidate families, including genetically modified taNK, haNK and t-haNK product candidates, will require significant additional clinical testing;

• even if we successfully develop and commercialize our aNK product candidates or N-803, we may not be successful in developing and commercializing our other product candidates either alone or in combination with other

therapeutic agents;

• we may not be able to file INDs, to commence additional clinical trials on timelines we expect;

• we will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates; and

• risks associated with our ability to enforce intellectual property rights.

Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” or similar expressions and the negatives of those terms.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other risks regarding our business are described in detail in NantKwest’s Securities and Exchange Commission filings. We encourage you to review NantKwest’s SEC filings in order to understand these risks. These forward-looking statements speak only as of the date thereof, and we disclaim any obligation to update these statements except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation.

Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. No representation or warranty, express or implied, is given as to the completeness or accuracy of the information or opinions contained in this document and we do not accept any liability for any direct, indirect or consequential loss or damage arising from reliance on such information or opinions. Past performance should not be taken as an indication or guarantee of future performance. You should read this presentation completely and with the understanding that our actual future results may be materially different from what we expect.

2

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

B=3+>9)44+B0<C+)?+&=3+!""#$3+D'4&3"+%$+>0$,39!$E#,%$:+!""#$):3$%,+>3<<+F30&=

B=3+>9)44+B0<C+)?+&=3+!""#$3+D'4&3"+%$+>0$,39!$E#,%$:+!""#$):3$%,+>3<<+F30&=

!"#$%&!"#$%&!%''

()*+&,-$&+%#.-&+#*%#/

B93: 8FD>4

8@+80,9)G=0:34

0112/3%243%'15675!%'' 89:5;%'%/%<5=<%#+.-&)> ?@2AB5C)>-+#5D&+/%-#

H

6"/)&"'57-''%&E67F5!%''

675!%''52 G+&#5/+57-''H/0&#93I4+1%<<39+>3<<

!$$0&3+!""#$3+D'4&3"

/1J@F

89:5;%'%/%<5=<%#+.-&)>

;%#<&-/-$5!%''

;%#<&-/-$5!%''52 (3%5(&"-#%&H/0&#93I4+B90%$39+>3<<

B=3+>9)44+B0<C+(3&233$+!$$0&3+.+KE0G&%L3+!""#$3+D'4&3"

,%*+&I57-''%&(5!%''

(5!%''52 (&"-#%<5/+57-''H/0&#93I4+B09:3&3E+1%<<39

KE0G&%L3+!""#$3+D'4&3"

B>M

>9)44+B0<C >9)44+B0<C

/KDFKNO+/1

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

BC>D+@AEFG+C3"%$0<+H%4,)I39'+J'+/B/K+)?+/3)3L%&)L3+C%<3$,%$:

M

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A


!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A


M

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

B=3+/C/B+D%4,)E39'+)?+&=3+B#")94+CF%<%&'+&)+GE0H3+.+I%<3$,3+&=3+!""#$3+I'4&3"B=3+/C/B+D%4,)E39'+)?+&=3+B#")94+CF%<%&'+&)+GE0H3+.+I%<3$,3+&=3+!""#$3+I'4&3"

!"#$%&

B93: 8DI>4

8@+80,9)J=0:348@+80,9)J=0:34

'%#(&)*)$+!%,,-%./&0+1),,%&

2+!%,,

I#JJ9344

;%H3

23./&45+'%6%#5%

D%40F<3

83&04&04%K3

L

7"*3&",+1),,%&8719+!%,,

CI>M+@ANO

7"*3&",+1),,%&8719+!%,,

'%#(&)*)$+!%,,-%./&0+1),,%&

2+!%,,

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$$%&'()*''+",!+''$

/3B&+C3$390&%)$+!""#$)&=390D'/3B&+C3$390&%)$+!""#$)&=390D'

!&-.+"

/01#"2*."#+-3*"#-1+-%

E93: 8FG>4

8@+80,9)D=0:34

!"#$$%&'(!"#$$%&'()*''+",!+''$4+-5"*%*.,!+''6&%0"&',)*''+"

76)8,!+'' 2+1#"9,)*''+"/,!+''

E9%0$:<3+H??3$43I+G%"#<&0$3)#4+J,&%K0&%)$+)?+/1*+F3$L9%&%,+0$L+E+>3<<4

M

()9$+&)+1%<<I/0&#93N4+1%<<39+>3<<

!$$0&3+!""#$3+G'4&3"

E=3+E90%$39I/0&#93N4+E90%$39+>3<<

E=3+>9)44+E0<O+(3&233$+!$$0&3+.+JL0D&%K3+!""#$3+G'4&3"

E90%$3L+&)+1%<<I/0&#93N4+E09:3&3L+1%<<39JL0D&%K3+!""#$3+G'4&3"

/:+,6;6/,!&-.+",<&..*-+E=3+70&=+&)+>)"D<3&3+P3"%44%)$I+

Q$<304=%$:+&=3+E9%0$:<3+H??3$43+)?+1%<<39+>3<<4+

6&%0"&',)*''+"6&%0"&',)*''+"

2*."#+-3*"#-1+-%

8@+80,9)D=0:34

=110-#1#50'&%+,%:+,/01#",=%$+'>,&$,&,<&..*-+,74;2?$8,&-5,/"&-$>#"1,%:+,2*."#+-3*"#-1+-%,%#,@3+".#1+,A0BB"+$$*#-,72+%"#-#1*.,/:+"&B98

/+1B#"&',AB&%*&',@".:+$%"&%*#-#>,6),C,/,!+''$,/#D&"5$=110-#E+-*.,!+'',4+&%:

RBD)43

>)"D<3&3+P3"%44%)$

Q$<304=

/"*&-E'+,@>>+-$+

1%<<

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!""#$% &#!'($!B3$&%?%3B 0$B+C3D3<)E3B+13'+F%94&G%$G><044+H:3$&4+C9%D%$:+!""#$):3$%,+>3<<+C30&=

I

!""&)*+"&($,--+./0+1/02-$)*

H,&%D0&3B+/1+>3<<+J%$3+K%&=)#&!$=%L%&)9'+M3,3E&)94

!""#34567680$9)64+:6;2<=6702>

N90$4,'&)4%4+&)+&=3+N#")9+8%,9)3$D%9)$"3$&

H,&%D0&%)$+)?+8@+80,9)E=0:34

&#!?@&4$A020=0B$3B08CD<5EFO3$)"%,0<<'+!$?)9"3B+

C3$B9%&%,+>3<<

!"#"$%&'(')

*+,-'.'/-012+(-$

!"#$%&'()*+'(,)$

&#!'32BC7C5E4<;<8

N90$4,'&)4%4+&)+&=3+N#")9+8%,9)3$D%9)$"3$&

CH87+H,&%D0&)9

&#!')686=<8CF=6=

PE%:3$3&%,+H,&%D0&%)$)?+8;>Q

&#!?)+G#H$IJ+!?$KEF<C8$:5C=0<8

H,&%D0&%)$+)?+/1+.+83")9'+N+>3<<4

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$% B$$)#$,3+>0$,39+(930C&=9)#:=4+@A@A

D

!"#&%'EF&0%$+GHB+B#&=)9%I0&%)$+&)+J34&+/)K3<L/)K3<+!""#$)<):%,0<+>)"F%$0&%)$4+5 MN!OJJ=3+/B/J+>0$,39+P0,,%$3Q+J=3+J9%0$:<3+E??3$43

#(("') !"#&%'13'+G%94&L%$L><044+!""#$):3$%,+>3<<+H30&=+B:3$&4

!"#&') !"#(Q+H3")$4&90&3+R09<'+S%:$0<4+)?+H#90F<3+>)"T<3&3+U3"%44%)$

!"!"'* !"!+Q+G)93,04&+?)9+GHB+BTT9)K0<4+%$+8#<&%T<3+J#")9+J'T34+

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'$()*$+,-./0

/BCAD /BCAD /BCAD /BCAD /BCAD /BCAD

(>E F%&#G#"0H 0/1 (>E 73"H9)I/%J) 73"H9)

K4& L%$3+/8!(>(<0MM39

@$M .+D9M+L%$3+%/;L

@$M .+D9M L%$3+839N3<+>3<<>09,%$)"0

@$M L%$3/8!(>(<0MM39

D9M L%$3+>=3,NO)%$&+F3<0O43/P>L>

K4& L%$383&04&0&%,/P>L>

QR!LSB@-AAT QR!LSBD-AA@ QR!LSBD-AAU QR!LSBD-AD@ QR!LSBD-ATT QR!LSB@-A@D

V04&+S90,N+++++++7=043+@W 7=043+K+I+@ 7=043+@

(930N&=9)#:=7=043 @W

7%J)&0<7=043+@W

7%J)&0<7=043+@W

/>SA@KDCXDY />SA@DCYUTY />SA@YZTUTX />SADA@@C@T />SAD@@CZZX />SADT@AZCZ

1$()*$+,-./0

=0/1 7[BLK+&B=0/1

/BCAD /BCAD

\J3<#"0H \<M)G)9#H%,%$

@$M .+D9M L%$3+839N3<+>3<<+>09,%$)"0

@$M L%$383&04&0&%,+70$,930&%,>0$,39

QR!LSBD-AZD 4O!/[

7%J)&0<7=043+@W 4O!/[

/>SADCTDDKX 4O!/[

234-$%5'$()*$+,-./0

\M!>]\ \M!>]\

^3BF04 ^3BF04

0/1 =0/1

/BCAD /BCAD

\J3<#"0H \J3<#"0H

@$M .+D9M L%$3+83&04&0&%,70$,930&%,+>0$,39

@$M .+D9M L%$3+83&04&0&%,+70$,930&%,+>0$,39

QR!LSBD-ADU QR!LSBD-AZA

7=043+!H+I+!! 7=043+!H+I+!!

/>SADKDZYAZ />SADD@U@YC

637$%8'()*$+,-./0

\<M)G)9#H%,%$

\M!>]\

^3BF04

0/1

/BCAD

\J3<#"0H

@$M .+D9M L%$3+83&04&0&%,+70$,930&%,>0$,39

QR!LSBD-AXA

7=043+!H+I+!!

/>SADDCXAUC

!-.$%9:'()*$+,-./0

\MB8R>K

\MB(90,='

^3B(90,='

^3B>]\

\<M)G)9#H%,%$

\M!>]\

^3BF04

=0/1

/BCAD

\J3<#"0H

D9M L%$3+83&04&0&%,S/(>

QR!LSBD-AZX

7=043+!H+I+!!

/>SADDCXACT

;<-4-.$%99'$()*$+,-./0

\MB;]F@ \MB;]F@ \MB;]F@

\MB8R>K \MB8R>K \MB8R>K

\MB(90,=' \MB(90,=' \MB(90,='

^3B(90,=' ^3B(90,=' ^3B(90,='

^3B>]\ ^3B>]\ ^3B>]\

\<M)G)9#H%,%$ \<M)G)9#H%,%$ \<M)G)9#H%,%$

\M!>]\ \M!>]\ \M!>]\

^3BF04 ^3BF04 ^3BF04

=0/1 =0/1 =0/1

/BCAD /BCAD /BCAD

\J3<#"0H \J3<#"0H \J3<#"0H

D9M+L%$3+83&04&0&%,+

;30M+.+/3,N

D9M L%$3++83&04&0&%,+

F0$M)"%_3M+>)<)93,&0<

@$M .+D9M L%$3+83&04&0&%,+70$,930&%,+>0$,39

QR!LSBD-AUA QR!LSBD-AXK QR!LSBD-ACA

7=043+!H+I+!! 7=043+!H+I+!! 7=043+!H+I+!!

/>SADDCXKKK />SADTZDKTX />SADTCZCZU

V3H+@AKU P3O+@AKU 80'+@AKX /)J+@AKX [3,+@AKX [3,+@AKX 6#<+@AKC6#$+@AKC[3,+@AKX60$+@AKX80'+@AKY 80'+@AKC6#<+@AKX809+@AKT 6#$+@AKT!$%&%0&%)$+[0&3

>0$,39+(930N&=9)#:=4+@A@A`+7=043+!+I+!!+S9%0<4+&)+S34&+&=3+;'O)&=34%4+)?+&=3+aS9%0$:<3+b??3$43c+

%$+8#<&%O<3+S#")9+S'O34+d@AKY+5 @AKUe

!"#$%&'&()*"++

,-'.%-+)/&++"%0,/1)*"++

2"34%5)/&++"%6)*"++*%477'-+8

/&++"%)*"++7

KIKXI@A KA

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'$()*$+,-./0

/BCAD /BCAD /BCAD /BCAD /BCAD /BCAD

(>E F%&#G#"0H 0/1 (>E 73"H9)I/%J) 73"H9)

K4& L%$3+/8!(>(<0MM39

@$M .+D9M+L%$3+%/;L

@$M .+D9M L%$3+839N3<+>3<<>09,%$)"0

@$M L%$3/8!(>(<0MM39

D9M L%$3+>=3,NO)%$&+F3<0O43/P>L>

K4& L%$383&04&0&%,/P>L>

QR!LSB@-AAT QR!LSBD-AA@ QR!LSBD-AAU QR!LSBD-AD@ QR!LSBD-ATT QR!LSB@-A@D

V04&+S90,N+++++++7=043+@W 7=043+K+I+@ 7=043+@

(930N&=9)#:=7=043 @W

7%J)&0<7=043+@W

7%J)&0<7=043+@W

/>SA@KDCXDY />SA@DCYUTY />SA@YZTUTX />SADA@@C@T />SAD@@CZZX />SADT@AZCZ

1$()*$+,-./0

=0/1 7[BLK+&B=0/1

/BCAD /BCAD

\J3<#"0H \<M)G)9#H%,%$

@$M .+D9M L%$3+839N3<+>3<<+>09,%$)"0

@$M L%$383&04&0&%,+70$,930&%,>0$,39

QR!LSBD-AZD 4O!/[

7%J)&0<7=043+@W 4O!/[

/>SADCTDDKX 4O!/[

234-$%5'$()*$+,-./0

\M!>]\ \M!>]\

^3BF04 ^3BF04

0/1 =0/1

/BCAD /BCAD

\J3<#"0H \J3<#"0H

@$M .+D9M L%$3+83&04&0&%,70$,930&%,+>0$,39

@$M .+D9M L%$3+83&04&0&%,+70$,930&%,+>0$,39

QR!LSBD-ADU QR!LSBD-AZA

7=043+!H+I+!! 7=043+!H+I+!!

/>SADKDZYAZ />SADD@U@YC

637$%8'()*$+,-./0

\<M)G)9#H%,%$

\M!>]\

^3BF04

0/1

/BCAD

\J3<#"0H

@$M .+D9M L%$3+83&04&0&%,+70$,930&%,>0$,39

QR!LSBD-AXA

7=043+!H+I+!!

/>SADDCXAUC

!-.$%9:'()*$+,-./0

\MB8R>K

\MB(90,='

^3B(90,='

^3B>]\

\<M)G)9#H%,%$

\M!>]\

^3BF04

=0/1

/BCAD

\J3<#"0H

D9M L%$3+83&04&0&%,S/(>

QR!LSBD-AZX

7=043+!H+I+!!

/>SADDCXACT

;<-4-.$%99'$()*$+,-./0

\MB;]F@ \MB;]F@ \MB;]F@

\MB8R>K \MB8R>K \MB8R>K

\MB(90,=' \MB(90,=' \MB(90,='

^3B(90,=' ^3B(90,=' ^3B(90,='

^3B>]\ ^3B>]\ ^3B>]\

\<M)G)9#H%,%$ \<M)G)9#H%,%$ \<M)G)9#H%,%$

\M!>]\ \M!>]\ \M!>]\

^3BF04 ^3BF04 ^3BF04

=0/1 =0/1 =0/1

/BCAD /BCAD /BCAD

\J3<#"0H \J3<#"0H \J3<#"0H

D9M+L%$3+83&04&0&%,+

;30M+.+/3,N

D9M L%$3++83&04&0&%,+

F0$M)"%_3M+>)<)93,&0<

@$M .+D9M L%$3+83&04&0&%,+70$,930&%,+>0$,39

QR!LSBD-AUA QR!LSBD-AXK QR!LSBD-ACA

7=043+!H+I+!! 7=043+!H+I+!! 7=043+!H+I+!!

/>SADDCXKKK />SADTZDKTX />SADTCZCZU

V3H+@AKU P3O+@AKU 80'+@AKX /)J+@AKX [3,+@AKX [3,+@AKX 6#<+@AKC6#$+@AKC[3,+@AKX60$+@AKX80'+@AKY 80'+@AKC6#<+@AKX809+@AKT 6#$+@AKT!$%&%0&%)$+[0&3

=>.?-@$A@->B/C@#D,C0$&:&:E;43F-.?-$#G$;>@<H$63,.><0$#G$ID@>J<-$=#KL<-/-$M-K3003#.$3.$ND</3L<-$!DK#@$!HL-0

TU+)#&+)?+KAT+`TZab+>)"O<3&3+F34O)$434+%$+X+S#")9+S'O34ZU+)#&+)?+KZK+`YKab+cJ390<<+F34O)$43+F0&3+%$+C+S#")9+S'O34

!"#$%&'&()*"++

,-'.%-+)/&++"%0,/1)*"++

2"34%5)/&++"%6)*"++*%477'-+8

/&++"%)*"++7

KK

=#KL<-/-M-0L#.0-

=#KL<-/-M-0L#.0-

=#KL<-/-M-0L#.0-

=#KL<-/-M-0L#.0-

ID@>J<-M-0L#.0-

ID@>J<-M-0L#.0-

=#KL<-/-M-0L#.0-

=#KL<-/-M-0L#.0-

=#KL<-/-M-0L#.0-

ID@>J<-M-0L#.0-

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

B@

!,=>8%*%'B';-&"<8%'?%/>,#/%/'5#'C64"#$%6'@%*"/*"*5$';5/%"/%'C$&,//'@-8*5>8%'A-=,&'A9>%/

DE'B'A'!%88'C$*54"*,&

F77G*+%G:+%87D"*-&"8'E588%&'!%88'H5#%

DGI1J

+"DEK;GHL'*G+"DE

CD+)#&+)?+BAC+ECFGH+>)"I<3&3+J34I)$434+%$+K+L#")9+L'I34

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

BC

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>D+/0EF3+(<0GG39+>0$,39+H7=043+!I D'E'D'!? F'0G'@,#*+/

(>D+J$934K)$4%F3+>!L+(<0GG39+>0$,39+H7=043+!!I HG'E'GI'!? H'J 0D'@,#*+/K'L#.,5#.

C9G M%$3+N3<0K43G+.+N3?3,&)9'+>=3,OK)%$&/)$PL"0<<+>3<<+M#$:+>0$,39 M1'E'NI'L?? 0'J GN'@,#*+/

K'L#.,5#.

C9G M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$G)<3$&+/)$P;)G:O%$+M'"K=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30G+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43

C9G M%$3+S9%K<3+/3:0&%F3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+M)2+R)43

@$G M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/


C9G M%$3+N3<0K43G+.+N3?3,&)9'+>=3,OK)%$&/)$PL"0<<+>3<<+M#$:+>0$,39 M1'E'NI'L?? 0'J GN'@,#*+/

K'L#.,5#.

C9G M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$G)<3$&+/)$P;)G:O%$+M'"K=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30G+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43

C9G M%$3+S9%K<3+/3:0&%F3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+M)2+R)43

@$G M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

(<0BB39+>0$,39+5 >)"C<3&3+D34C)$43+%$+E+)?+E+70&%3$&4!"#$%&'/>FA@GHIJHKLM!NF+@-AAO

7=043+!++P/QER(&)*+,-&./&'0*1#2%$34#5&678&30&7.9:30#*3.0&;3*"&<=>?@&30&!#*3%0*$&;3*"&<.0=A+$45%&'02#$32%&65#,,%1&7#04%1

B.$%C30*1#2%$34+5#1&30$*355#*3.0D

!#*3%0*& )*#E%F%$G.0$%&($$%$$9%0*$

;HI JA KA HIA HLA H>A IHA !"#

GAA+S:G 70C+FG 7FM 7F 7F 7F 7F 7F 7F 7F@ 70C+F0 7FM 7F 7F 7F 7F 7F 7F 7FH 70C+FG 7FM 7F 7F 7F 7F 7F 7F 7F

@AA+S:

K 70C+FG '7 7FM 7F 7F 7F 7F 7F 7F

O >!T '7 '7 '7 7F 7F 7F 7F 7F

U 70C+FG 7FM 7F 7F 7F 7F 7F 7F 7F

KAA+S:

J 70C+FG 7FM 7F 7F 7F 7F 7F 7F 7F

I >!T 7FM 7F 7F 7F 7F 7F 7F 7FMM

E 70C+F0 7FM 7F 7F 7F 7F 7F 7F 7F

/VIAH+W+(>X+%$+;%:=VD%4Y+/8!(>+5 7=043+! D34#<&4Z#90[<3+>)"C<3&3+D34C)$434+P>DR+)9+/)+D3,#993$,3+P/DR+%$+E+)#&+)?+E+70&%3$&4

K&./&K&CH??ND&!#*3%0*$&B3$%#$%=O1%%&#*&IP&A.0*"$BCG naïve alone (SoC): Historical response rate is 55-75% at 3-6 months post BCG alone

Based on this data, FDA granted Fast Track Designation to the Pivotal Trial*CR termed as No Recurrence (NR) in Papillary Disease **Negative Cystoscopy Inconclusive Cytology

GK

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

BC

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>D+/0EF3+(<0GG39+>0$,39+H7=043+!I D'E'D'!? F'0G'@,#*+/


M9G N%$3+O3<0K43G+.+O3?3,&)9'+>=3,PK)%$&/)$QL"0<<+>3<<+N#$:+>0$,39 M1'E'NI'L?? 0'J GN'@,#*+/

K'L#.,5#.

M9G N%$3+839P3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$G)<3$&+/)$Q;)G:P%$+N'"K=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

R&= N%$3+;30G+.+/3,P+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+N)2+S)43

M9G N%$3+T9%K<3+/3:0&%F3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+N)2+S)43

@$G N%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+N)2+S)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/


K'L#.,5#.

M9G N%$3+839P3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$G)<3$&+/)$Q;)G:P%$+N'"K=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

R&= N%$3+;30G+.+/3,P+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+N)2+S)43


@$G N%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+N)2+S)43

(>D+/0EF3+(<0GG39+>0$,39+H7=043+!I D'E'D'!? F'0G'@,#*+/QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!"#$%&'"()*'+,#-.*/$&.(/+!"#$%&'(&$)*(+,-'$(+,$*,./0,1*'"%2)*%$3",/45,674./

8*9 :$*",6;<=>,?,./0

0/1.2$&.(/+$/1+3)4("+356# ,#-.*/ 7$&.#/&-+

8/"(99#1 :;+;$&# :5-&#2&(45+<=(.1$/2#

>$?#&5+@+3(9#"$A.9.&5

8*9 :$*"./0 1*'"%2)*%$3",

/45

5$*#+",@'AB./0,?,6;<=>

6,C,<=

BB+C+DE&),D(&"

FGH+/)A2+"&",!"%2)*%"

DIH/E%&"F&)AE,

G'""

JHH$&I,&'"(&A"*&,'"+(&"9,5@J%

KL

!"#$%&!"#$%&'()*+%,-."

'( )*!"#$

+,-./012-0314)* )*

/51+,-.3(12-6614

%&'( )*+,-.+/01$*.2$

+,3-

01$4$

35.+6/

01$7$

35.+6/

01$8$

35.+6/

01$"9$

35.+6/

:;<=4$>$?0@ AAB4#

+,-.0712-8014C.(5,.($D+'E2

!"#$%&'()*#+$,-%+./"0,!%(&%(/1,2"3("4,5&%,6%"+/#"./,&5,!+/("./7,8(/9,:;<=> !"#$%&%&

D2/+-3,F$G6-&*H2$; I"=#$JEK-&/-$LK-.+/

9":-/53'

M5F*N$G6-&*H2$O "#$JEK-&/-$LK-.+/

?&-*P+6&5'(6$%-/,(.*+,5.$

;"<=>?%@?=&A@B-C%=@B-=A-D+E-FA%">G&A>=H"-+,I-)J,D+/AK L=A"-)M856-N-D+E-+&#G@%"K-?&-!"#$%& 9":"#$"%-*GG%&H@B

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

BC

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>D+/0EF3+(<0GG39+>0$,39+H7=043+!I D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

M9G N%$3+839P3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$G)<3$&+/)$Q;)G:P%$+N'"K=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

R&= N%$3+;30G+.+/3,P+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+N)2+S)43


@$G N%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+N)2+S)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/

M9G N%$3+839P3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$G)<3$&+/)$Q;)G:P%$+N'"K=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

R&= N%$3+;30G+.+/3,P+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+N)2+S)43


@$G N%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+N)2+S)43

(>D+/0EF3+(<0GG39+>0$,39+H7=043+!I D'E'D'!? F'0G'@,#*+/


QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%#$#&'()*+,-.$//(0"//(12+3(0$+'"4(5)-0106(/BCAD+%$+>)"E%$0&%)$+2%&=+/%F)<#"0E+%$+D9G H%$3+)9+I930&39+70&%3$&4+

7"/$8%"9($+9(7":4$'#*4;(#*()&<*(*4(0=".*

JK

>::&'$';(>+98*&+#

?//(@$#&"+#%(>+4*//"9(5+ABC6

@D,1E(F(BGH(5+AEC6

!"9&$+(@4*34"%%&*+(I4""(-24<&<$/

D-L+8)$&=4M@-N*+L-JO

P-L+8)$&=4MJ-P*+C-LO

!"9&$+(J<"4$//(-24<&<$/

JD-P+8)$&=4MK-Q*+JK-LO

JN-J+8)$&=4MP-Q*+J+3*&+3O

J<"4$//(7"%8*+%"(7$#" JCR KLH

-#$M/"(D&%"$%" PLR DCR

D&%"$%"(0*+#4*/(7$#" QDR NLR

60$+J@*+@A@AS+79343$&3G*+7<3$09'+T344%)$S+T%U&=+VV>WB!VTH>+

!$&39$0&%)$0<+6)%$&+>)$?393$,3S+H#$:+>0$,39+X90$4<0&%)$0<+T,%3$,3+?9)"+&=3+

(3$,=+&)+&=3+><%$%,

ImmunityBio, Inc. & NantKwest Inc. – JP Morgan Healthcare Conference 2020

N-803 When Combined with Nivo Appears to Reduce AE’s Associated with Checkpoint Inhibitors

Agent Trial Immune Related AEsGrade 3 or higher

Nivo + N-803 NCT02523469 7%

Nivo Alone Checkmate 57 ~14%

Pembro Alone Keynote 10 ~15%

Comparison of Immune Related AEs in 2nd Line Treatment of NSCLC

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

@B

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/

(>C+I$934J)$4%E3+>!K+(<0FF39+>0$,39+G7=043+!!H HG'E'GI'!? H'J 0D'@,#*+/K'L#.,5#.

L9F M%$3+N3<0J43F+.+N3?3,&)9'+>=3,OJ)%$&/)$PK"0<<+>3<<+M#$:+>0$,39 M1'E'NI'L?? 0'J GN'@,#*+/

K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43

L9F M%$3+S9%J<3+/3:0&%E3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+M)2+R)43

@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43


@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!"#$%%&'($"()*+(,#-)%(.)/&%-"&(0)1(23

4-#/,(5"67/-$"($"(2893:9;23<

!"#$%#&!$' !"#"!#&!$'0)1(3=

!'#&$#&!$'0)1(>>

*$(*&?(@&/-$"/A-"B&(2893=9;23<

$&#&!$%(C6,&#(DE(F%7/(54*(F%7/(5G-H7-G$'(

$!#&!$%4-#/,(B$"/7%,),-$"(),(IJK(A&),,%&

!%#&!$))",-LM0L3()6,&#(3;(?&&N/($6(

F&GO#$%-P7G)OM&GO#$%-P7G)O '-/B$",-"7&'('7&(,$(F#$Q#&//-R&('-/&)/&

D&B&-R&'("&7,#$"(DE(,$(/B)%F()"'(.9@("&BN(,7G$#/S

!*#&!$) $&#&!$)D&B7##&",(TUU(,7G$#/($"(

/B)%FS

!$#&!$)D&B7##&",(TUU("$'7%&/($"(

/B)%F(-"(DE(6-&%'/S(A,)#,&'()",-LM0L3(VF&GO#$%-P7G)OW(6$#(

7"#&/&B,)O%&(TUU

!'#&!$)!"#$%%&'($"()(B%-"-B)%(,#-)%($6(-",#)%&/-$")%

E@DL=()Q$"-/,(F%7/(DE(

MX)/&(5955Y(U$GF%&,&(D&/F$"/&(-"(+,-.,/(0,//(01-234561JX$(4)-%&'(UX&BNF$-",/(Z(M#&R-$7/(UX&G$,X&#)F1

!7#!$#&!$'0)1(3[3

*$(*&?(@&/-$"/A-"B&(2893=9;23<

;;

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A70:3+@B

!"#$%&#'"($)%'"&*'*$+%"+%',-%%'#.'*"#%/01234'5"6+7'893':%"-+'; <+'.,'="&'001'2>2>?

C930&"3$&+!$%&%0&%)$+5 D#:#4&+@AEF/)+C930&"3$&+G%$,3+6#<'+@AEH

I#90J<3+>)"K<3&3+L34K)$43+M@+8)$&=4+0$N+O$:)%$:

I#90J<3+>)"K<3&3+L34K)$43+%$+839P3<+>3<<+>09,%$)"00/1 0<)$3+?)<<)23N+J'+>=3,PK)%$&

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

@B

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

B&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+Q)43

L9F M%$3+R9%J<3+/3:0&%E3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+M)2+Q)43

@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+Q)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/

B&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+Q)43

L9F M%$3+R9%J<3+/3:0&%E3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+M)2+Q)43

@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+Q)43

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

9%&#B%"0CD0$&%E>F@A+"GCH

/EIAJD!KELM+N#O39

G:)$%4&+>)"O<3BH

LMP0

!:QLR,

!KLM/S@F

TP3<U93?+!$V)<3$&

/)$E;)V:W%$K'"O=)"0

P3<0O43V+!$V)<3$&+/)$E;)V:W%$X4+K'"O=)"07=043+LU@+><%$%,0<+Y9%0<+)?+/EIAJ+7<#4+P%&#B%"0C

!"#$%&"#'()#" *+,- ./012

3& 4%.4562

7P A+DAZH

[PP S+DSIZH

NF @+D@@ZH

7F A+DAZHSIZ+>P+P0&3

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

@B

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43


@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/


@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'&()&#*++*",(-"+'!.,/&0(1&#"02(3.//*,&(

40&.'#&,'B?&39+@C>',<34

!4(5!67-.'*&,'8(9:;:<::=>::?

-0&>40&.'#&,'@'A B*,&

-C4(5!67

!4(5!67

!"#$%&'&()&+$",+&(*,(@'AB*,&(1&'.+'.'*/(D&.E(F(7&/G(!.,/&0(6H'&0(?(!2/%&+

D+,"E#")9+8044

F0%<3G+H0G%0&%)$*+>=3")*+>=3,IJ)%$&KD&= L%$3M

N$J#O<%4=3G+P0&0

4I#"0(1.++(!"#$%&'&%2()&+"%J&E(6H'&0(K:(L.2+(M?(!2/%&+N(OI%2(=@N(?:=PQ

@(/#4I#"0(1.++

R.*%&E().E*.'*",N(!A&#"N(!A&/G$"*,'

M@'A B*,&Q

!"#$%&'&()&+$",+& !"#$%&'&(

)&+$",+&

@Q

@'A B*,&()&%.$+&E(D&.E(.,E(7&/G(!.,/&0

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

@B

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43


@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/

@$F M%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+M)2+R)43

(>C+/0DE3+(<0FF39+>0$,39+G7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

L9F M%$3+839O3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$F)<3$&+/)$P;)F:O%$+M'"J=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

Q&= M%$3+;30F+.+/3,O+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+M)2+R)43

QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

-100%

-80%

-60%

-40%

-20%

0%

20%

40%

Baseline Scan 1 Scan 2 Scan 3 Scan 4 Scan 5 Scan 6 Scan 7

% C

hang

e fro

m B

asel

ine

Legend

Stable DiseasePartial Response

Complete ResponseWithdrew

X = Off-Study

3rd Line Triple Negative Breast CancerBest Response by Resist 1.1

-30% Partial Response

20% Progression

2 Months 4 Months 6 Months 8 Months 10 Months 12 Months 14 Months

Jan 11, 2020

X002X004

X003

SD 006PR 003

X010 X001

CR 008

CR 009

Presented at 2019 San Antonio Breast Cancer Symposium

ORR: PR + CR: 6 / 9 (67%)Complete Response: 2 / 9 (22%)Disease Control: 8 / 9 (89%)

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

B$,)#90:%$:+B??%,0,'+C%:$0<4+2%&=+>)"D%$0&%)$+E=390F'

!"#$%&'()*+/G/E+E9%F<3+/3:0&%H3+(9304&+>0$,39+IE/(>J+K0,,%$3L+

8)<3,#<09<'+!$?)9"3M+!$&3:90&3M+!""#$)&=390F'+%$+C#DN3,&4+O%&=+E/(>+O=)+;0H3+79):93443M+)$+)9+G?&39+

C&0$M09MP)?P,093+E=390F'-

,-./0%-&)1*

*2342562728296:2;<=2;>2?2@A=BCD=E2FCE@;DGCG2223*+H2066:242;<=2;>2?2@A=BCD=E2IAG2J;K@LC=C2FCE@;DEC222222344H256:

12;<=2;>2?2@A=BCD=E2IAG2GBECAEC2J;D=F;L22231?H2M56:

?2;<=2;>2N+)2@A=BCD=E2FCE@;DGCG2223O('H2066:42;<=2;>2N+)2@A=BCD=E2IAG2J;K@LC=C2FCE@;DEC2223N(4H256:222

N'2;<=2;>2N+)2@A=BCD=E2IAG2GBECAEC2J;D=F;L2223+(*H2M56:QA

G4+)?+60$+@A@A

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

BC+)#&+)?+DAB+EBFGH+>)"I<3&3+J34I)$434+%$+K+L#")9+L'I34FC+)#&+)?+DFD+EMDGH+NO390<<+J34I)$43+J0&3+%$+P+L#")9+L'I34

QD

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>R+/0SO3+(<0TT39+>0$,39+E7=043+!H D'E'D'!? F'0G'@,#*+/

(>R+U$934I)$4%O3+>!V+(<0TT39+>0$,39+E7=043+!!H HG'E'GI'!? H'J 0D'@,#*+/K'L#.,5#.

Q9T W%$3+J3<0I43T+.+J3?3,&)9'+>=3,XI)%$&/)$YV"0<<+>3<<+W#$:+>0$,39 M1'E'NI'L?? 0'J GN'@,#*+/

K'L#.,5#.

Q9T W%$3+839X3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$T)<3$&+/)$Y;)T:X%$+W'"I=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

M&= W%$3+;30T+.+/3,X+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+W)2+Z)43

Q9T W%$3+L9%I<3+/3:0&%O3+(9304&+>0$,39+ 0'E'D'!? D'J M0'@,#*+/K'L#.,5#. 83&9)$)"%,+W)2+Z)43

@$T W%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+W)2+Z)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/

(>R+/0SO3+(<0TT39+>0$,39+E7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

Q9T W%$3+839X3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$T)<3$&+/)$Y;)T:X%$+W'"I=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

M&= W%$3+;30T+.+/3,X+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+W)2+Z)43


QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!"#$%&'#()*+ ,-./01&-)123'34&562(&788696':&*+;<61='&>9&5./)9&!"#$%&?88#'(3#@(3A8&*+

B haNK cells engineered to incorporate CARs to target cancer cells displaying specific surface antigens

B Three modes of killing: via NK receptors, ADCC, and CAR directed killing

B ADCC and CAR-directed cytotoxicity are independent but synergistic

B Currently in Development:o PD-L1 t-haNK Phase I Completeo CD19 t-haNK IND Approvedo HER2 t-haNK IND Ready

5CDE&')*+%F%GFEH IE

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

@$B C%$3+83&04&0&%,+70$,930&%,+>0$,39+!"#$%&'&()&*$"+*&(,-'&.(/01&(23456('4789:

;+-<*0"+*(=0'7(94>?@

DD

A

EAA

FAAA

FEAA

@AAA

@EAA

DAAA

DEAA

GAAA

GEAA

EAAA

HIF@IFJ HIFJIFJ HI@KIFJ JI@IFJ JIJIFJ JIFKIFJ JI@DIFJ JIDAIFJ FAILIFJ FAIFGIFJ FAI@FIFJ FAI@HIFJ FFIGIFJ FFIFFIFJ FFIFHIFJ FFI@EIFJ F@I@IFJ F@IJIFJ F@IFKIFJ F@I@DIFJ F@IDAIFJ FIKI@A

3&A(@?B(C?6D!"+-0.#&E(!"#$%&'&()&*$"+*&

2FG(!G

H<%I(6CB(C?6D501&.(J&'8*'8*0*2"*0'01&(2FG(!G)&%8$*&(/K5/;);

9"1&#L&.(6MB(C?6D!"#$%&'&()&*$"+*&

2FG(!G

!,

6D4D

>=3")+8)B#<0&%)$ >=3")+8)B#<0&%)$/MHAD

7NMCF+&M=0/1

>=3")+8)B#<0&%)$/MHAD

7NMCF+&M=0/1O<B)P)9#Q%,%$

23456('4789: 94>?@

!,6D4D(5&1&%(E&A.&8*&*(-."#(MN>M('"(N?

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$%&'(&%")*+&,-.+/'010123456%#$%',7'3"&89':5.#"8/',7';-&"<8%'!,=>8%*%'?%=5//5,#'5#'@-8*5>8%'A-=,&'A9>%/

BC+)#&+)?+DAB+EBFGH+>)"I<3&3+J34I)$434+%$+K+L#")9+L'I34FC+)#&+)?+DFD+EMDGH+NO390<<+J34I)$43+J0&3+%$+P+L#")9+L'I34

QM

B#65$"*5,# ?%/>,#/%/ ;-&"*5,#',7'?%/>,#/% !+%=,*+%&">9'C&%%

(>R+/0SO3+(<0TT39+>0$,39+E7=043+!H D'E'D'!? F'0G'@,#*+/



K'L#.,5#.

Q9T W%$3+839X3<+>3<<+>09,%$)"0 0'E'O'!? HM'J GI'@,#*+/'K'L#.,5#.

!$T)<3$&+/)$Y;)T:X%$+W'"I=)"0 M1'E'0M'!? M1'J 0I'@,#*+/K'L#.,5#.

M&= W%$3+;30T+.+/3,X+>0$,39 M'E'G'!? O'@,#*+/ 83&9)$)"%,+W)2+Z)43


@$T W%$3+83&04&0&%,+70$,930&%,+>0$,39 M'E'D'!? 0'@,#*+/'K'L#.,5#. 83&9)$)"%,+W)2+Z)43

!,=>8%*%'K';-&"<8%'?%/>,#/%/'5#'P64"#$%6'@%*"/*"*5$';5/%"/%'P$&,//'@-8*5>8%'A-=,&'A9>%/

QR'K'A'!%88'P$*54"*,&

L77S*+%S:+%87Q"*-&"8'R588%&'!%88'T5#%

QSU1H

+"QRV;STM'*S+"QR

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$% B$$)#$,3+>0$,39+(930C&=9)#:=4+@A@A

DE

!"#&%'FG&0%$+HIB+B#&=)9%J0&%)$+&)+K34&+/)L3<M/)L3<+!""#$)<):%,0<+>)"G%$0&%)$4+5 NO!PKK=3+/B/K+>0$,39+Q0,,%$3R+K=3+K9%0$:<3+F??3$43

#(("') !"#&%'13'+H%94&M%$M><044+!""#$):3$%,+>3<<+I30&=+B:3$&4

!"#&') !"#(R+I3")$4&90&3+S09<'+T%:$0<4+)?+I#90G<3+>)"U<3&3+V3"%44%)$

!"!"'* !"!+R+H)93,04&+?)9+HIB+BUU9)L0<4+%$+8#<&%U<3+K#")9+K'U34+

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

>0$,39+(930B&=9)#:=4+@A@AC+7=043+!+D+!!+E9%0<4+&)+E34&+&=3+;'F)&=34%4+)?+&=3+GE9%0$:<3+H??3$43I+%$+8#<&%F<3+E#")9+E'F34

JK

!"#$ !"#% !"#& !"#$'!"#&

L)9"0<+!$&390,&%)$4+2%&= LMN OJP @KQ @RQ (%#

!/M4 N#&=)9%S3T+U'+LMN OJ @ J #%

7%V)&0<+W&#T%34+2%&=+X3:%4&90&%)$0<+!$&3$& Y O @ $

4F!/M4+!44#3T OO @K JQ $)

!$V34&%:0&)9Z%$%&%0&3T+[!!\Z!/M4+!44#3T P @ OY !#

L04&+E90,B+M34%:$0&%)$4 @ A O *

(930B&=9)#:=+E=390F'+M34%:$0&%)$ A A O #

LMN+NFF9)V0< A A O #

+,-./01234516708.409.-:1;736<416708

-=>:?60.@7:09A:?73.,-BC./09:523

DE.F.A.G2==.-516H4173

IJJ'1;2'K;2=JD41:34=.E6==23.G2==.L602

M06N:2.-9207H63:8,20936165.G2==.-516H4173

OP6Q202165.A:?73B796J623

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A BC

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

Q#")9+Q'N34+0$J+!$J%,0&%)$4+Q930&3J

:7+"#0.&;$"./!"#$%&<:=>&-./"1)%

*?&@&!&A)77&:130B23$%

C,,D3E)DFE)7,*23"%27&?077)%&A)77&G0.)

H.0I")&:/).$B0%"4<)./%0301&A)77&:130B23$%

J(0K).)301&!"#$%=$/0,0)%

/#"V39+)?+Q#")9+Q'N34 56

/#"V39+)?+!$J%,0&%)$4 89

!"#$%&!'()4&@&-./01230$.4&F3"/0)/&LMNOP&Q MNMNR

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A


JK

!"#$%&'(%)*+

L<M)N)9#O%,%$ ,-

/0$0&%$)4&0& ,

/PKAJ .//0&#90<+1%<<39+>3<<4

Q0/1*+=0/1*+7RPST+&P=0/1U ,-

LM3$)V%9#4 0

W7X+>0$,39+.+/3)3F%&)F3 /1

2)('$ 10

!3345637%385!"#$%&'(%)*+5.9,:5; .9,1<$#"=%*5>)"*?

2"=)45@<A!5B*?"&34

CD5E525F3$$5<&(%7'()4

GHH;(I3;JI3$HC'("4'$5D%$$345F3$$5K%*3

L*%M"35<?3*)7%4"+@3*?4%(%&5F3$$5<&(%7'()4

!"#$%&'&()*"++

,-'.%-+)/&++"%0,/1)*"++

2"34%5)/&++"%6)*"++*%477'-+8

/&++"%)*"++7

NO%P3*3(%&52"=)4A)?%H%34

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

B3<3,&3C+13'+7#D<%,0&%)$4

EF

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A


JA

!"#$#%&"'()#&"'*#+,-'.'/$0,-+#1&+2)-'3%+#0&+,4'56789': 678;<

3"=>?#$'@2>$4

(>?2)'A3BC'/$4>%,)

DE'.'('!,""'3%+#0&+2)

FGGH+I,H*I,"G

D&+>)&"'E#"",)'!,""'J#$,

K$#L>,'34,$20#)>-

A,$4)#+#%'!,""'3%+#0&+2)

K 679 ><%$%,0<+E9%0<+L%&34+M,&%N0&3OK 679 !$N34&%:0&)94K 67 ><%$%,0<+E9%0<4+M,&%N3<'+P$9)<<%$:K M8 L&0&34

!"#$%&'&()*"++

,-'.%-+)/&++"%0,/1)*"++

2"34%5)/&++"%6)*"++*%477'-+8

/&++"%)*"++7

NO#1,$,+#%'(>?2)

B24#G#,)

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

B??+&=3+C=3<?+/0&#90<+1%<<39+>3<<4+04+0+79)D#,&E+F)9<DG4+H09:34&+79)D#,&%)$+0$D+><%$%,0<+!$?#4%)$+)?+/0&#90<+1%<<39+>3<<4

IJ

!"#$%$&!"#$%$'()*+$,)&!"# -.+/$0 -.+1

233),&4)5&463$"!,78!6$#96648$:466;*9<4!86=$5>!6!?64@=$,&4$"7A?48;B

233),&4)5&463"!,78!6$#96648$:466$*9<4

>9')K93439L3D+B??M&=3MC=3<?/1+79)D#,&

B??M&=3MC=3<?+N$:%$3393D+/1MO@0/1*+=0/1*+7PMHJ+&M=0/1Q30D'+?)9+R90$4?#4%)$

J-S+R9%<<%)$+>3<<4+%$+C&)90:3

T-T+R9%<<%)$+>3<<4+80$#?0,&#93D

/#"U39+)?+>3<<4+80$#?0,&#93D+%$+V87+W0,%<%&'+&)+P0&3

CDC$E89669F<$:466;

/#"U39+)?+70&%3$&4+P)43D+04+B#&K0&%3$& GC

/#"U39+)?+P)434+XD"%$%4&393DYZ@+(%<<%)$+>3<<4+739+P)43[ /+1

/#"U39+)?+>3<<4+XD"%$%4&393D+&)+\T+70&%3$&4+C%$,3+@AJ] +DG$E89669F<$:466;

/#"U39+)?+>3<<4+%$+C&)90:3 +DH$E89669F<$:466;

/1+R930&"3$&+Q3<0&3D+>'&)^%$3+C&)9" I48F

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

>0$,39+(930B&=9)#:=4+C)93,04&+?)9+/3D&+C)#9+E3094

F@

!"#$%&!'()*&+&,-./012/$-* 3/4/-5&612)&3$%)01*2

787!&85)-2* 9&$:&;/2)*

9&$:&<12/)-2*800%").&2$&612)

8-2/0/(12).&=>8&?)5/*2%12/$-&3/4/-5*&@A@A&B @A@C

=41..)%&D1-0)%E (>G+H$934I)$4%J3/8!(>+>!K

@A@A FG&802/H)&;/2)* GG&I&JA7BJAF

CLM+(930B&=9)#:=

(<0NN39+>0$,39O+(>G+H$934I)$4%J3/8!(>+70I%<<09' @A@K FG&802/H)&;/2)* CA&I&JA7BJAF

CLM+C04&+P90,B

(<0NN39+>0$,39O+(>G+/0%J3/8!(>+>!K @A@F F@&802/H)&;/2)* CL&I&FMM7BJAF

CLM+C04&+P90,B

/)$QK"0<<+>3<<+R#$:+>0$,39O>=3,BI)%$&+S3<0I43N+T9N R%$3

@A@K7BJAF

J&I&CF@G&802/H)&;/2)*

/)$QK"0<<+>3<<+R#$:+>0$,39O7LQRU+VDI9344%)$+U4& R%$3

@A@F @J&802/H)&;/2)* KK&I&FJJ7BJAF

N)%O)4&D)44&D1%0/-$#1E>=3,BI)%$&+S3<0I43N*+@$N R%$3 @A@F F&802/H)&;/2)* K&I&CF

7BJAF P17Q

!%/(4)&7)512/H)&=%)1*2&D1-0)%T9N R%$3 @A@@

7BJAFA&I&CFP)+(3+WI3$3N<6B>K&2BP17Q84.$R

7$-B;#144&D)44&>"-5&D1-0)%E>=3,BI)%$&+S3<0I43N+@$N R%$3

@A@K7BJAF

KL&I&GG@G&802/H)&;/2)*

/)$QK"0<<+>3<<+R#$:+>0$,39O7LQRU+VDI9344%)$+K3,)$N+R%$3

@A@K P)+(3+WI3$3N A&I&GG7BJAF <6B>K&2BP17Q

=41..)%

N)21*212/0&<1-0%)12/0&D1-0)%@$N R%$3 @A@C

7BJAFA&I&KJJP)+(3+WI3$3N

<6B>K&2BP17Q84.$R

>"-5

!7=D

NDD

<1-0

,##"-/2'=/$ ,##"-/2'=/$ 71-2QS)*2

!$214&<12/)-2*&800%").&!$&612)&T&KJF&I&KFCK&&

=41..)%&D1-0)%ED$#(4)2)?)*($-*)

D$#(4)2)?)*($-*)

D$#(4)2)?)*($-*)

D$#(4)2)?)*($-*)

6"%1U4)?)*($-*)

6"%1U4)?)*($-*)

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

!"#$% B$$)#$,3C+>0$,39+(930D&=9)#:=4+@A@A

EF

#&&"'( !"#)%'13'+G%94&H%$H><044+!""#$):3$%,+>3<<+I30&=+B:3$&4+!C3$&%?%3C

!"#)'( !"#&%'FJ+!/I4+B#&=)9%K3C+2%&=+L@AA+!$M34&%:0&)9+N%&34+%$+EO+N&0&34

JE+7339+P3M%323C+N,%3$&%?%,+7#Q<%,0&%)$4

R=3+R9%0$:<3+S??3$43*+TU!VR+R9%0<4+>)"W<3&3C+2%&=+SM39+O+R9%<<%)$+/1+>3<<4+!$?#43C

>)"Q%$0&%)$+R=390W'+R34&3C+%$+FX+R#")9+R'W34+%$+EY+!$C%,0&%)$4

R#")9+8#&0&%)$+(#9C3$+?)9+R#")9H/)9"0<+R%44#3Z+G%94&+GIB+BWW9)M0<+%$+UN+5 S"%,4+>)93

I3")$4&90&3C+[09<'+N%:$0<4+)?+I#90Q<3+\J+>)"W<3&3+P3"%44%)$4+)#&+)?+OA\+N)<%C+R#")94+%$+8#<&%W<3+I%430434

!"#)%'SQ&0%$3C+GIB+B#&=)9%K0&%)$+&)+R34&+/)M3<H/)M3<H/)M3<+!""#$)<):%,0<+>)"Q%$0&%)$4

!"!"'* !"!+Z+G)93,04&+?)9+GIB+BWW9)M0<4+%$+8#<&%W<3+R#")9+R'W34

(930D&=9)#:=+N&0&#4+B,=%3M3C+?)9+(<0CC39+>0$,39

]+B,&%M3+P3:%4&90&%)$+R9%0<4+%$+(<0CC39*+V#$:*+0$C+839D3<+>3<<+>0$,39

/0$&1234&+.+!""#$%&'(%)+&)+!$&3:90&3+7<0&?)9"4+)?+/1+>3<<4*+/HYAF+0$C+B<C)^)9#Q%,%$

!""#$%&'(%)*+!$,-+.+/0$&1234&+!$,-+5 67+8)9:0$+;30<&=,093+>)$?393$,3+@A@A

B=3+>9)44+B0<C+)?+&=3+!""#$3+D'4&3"+%$+>0$,39!$E#,%$:+!""#$):3$%,+>3<<+F30&=

B=3+>9)44+B0<C+)?+&=3+!""#$3+D'4&3"+%$+>0$,39!$E#,%$:+!""#$):3$%,+>3<<+F30&=

!"#$%&!"#$%&!%''

()*+&,-$&+%#.-&+#*%#/

B93: 8FD>4

8@+80,9)G=0:34

0112/3%243%'15675!%'' 89:5;%'%/%<5=<%#+.-&)> ?@2AB5C)>-+#5D&+/%-#

HH

6"/)&"'57-''%&E67F5!%''

675!%''52 G+&#5/+57-''H/0&#93I4+1%<<39+>3<<

!$$0&3+!""#$3+D'4&3"

D;2@A5/23"67

89:5;%'%/%<5=<%#+.-&)>

3"67

;%#<&-/-$5!%''

;%#<&-/-$5!%''52 (3%5(&"-#%&H/0&#93I4+B90%$39+>3<<

B=3+>9)44+B0<C+(3&233$+!$$0&3+.+JE0G&%K3+!""#$3+D'4&3"

,%*+&I57-''%&(5!%''

(5!%''52 (&"-#%<5/+57-''H/0&#93I4+B09:3&3E+1%<<39

JE0G&%K3+!""#$3+D'4&3"

62JKL

>9)44+B0<C >9)44+B0<C

/JDFJLM+/1

JPM Final PSS 1 13 2020 for PDF - NantKwest...ImmunityBio, Inc. & NantKwest Inc. –JP Morgan...

Documents

Transcript of JPM Final PSS 1 13 2020 for PDF - NantKwest...ImmunityBio, Inc. & NantKwest Inc. –JP Morgan...